Sheng-Han Kuo

Sheng-Han Kuo

Auto-generated profile, based on publicly available information

Sheng-Han Kuo

Columbia University New York New York USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Neuron
Verified
Journal Article
Closed access
GTGuomei Tang
Guomei Tang
KGKathryn Gudsnuk
Kathryn Gudsnuk
SKSheng-Han Kuo
Sheng-Han Kuo
MCMarisa L. Cotrina
Marisa L. Cotrina
GRGorazd Rosoklija
Gorazd Rosoklija
DSDavid Sulzer
David Sulzer

3 March 2013 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
SOSamantha J Orenstein
Samantha J Orenstein
SKSheng-Han Kuo
Sheng-Han Kuo
ITInmaculada Tasset
Inmaculada Tasset
EAEsperanza Arias
Esperanza Arias
HKHiroshi Koga
Hiroshi Koga
ACAna Maria Cuervo
Ana Maria Cuervo
This study shows that Parkinson's disease–associated mutant forms of leucine-rich repeat kinase 2 (LRRK2) impair chaperone-mediated autophagy in neurons, thereby reducing degradation of α-synuclein by this pathway and contributing to the accumulation of this protein observed in brain tissue from patients with Parkinson's disease. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease. We found LRRK2 to be degraded in lysosomes by chaperone-mediated autophagy (CMA), whereas the most common pathogenic mutant form of LRRK2, G2019S, was poorly degraded by this pathway. In contrast to the behavior of typical CMA substrates, lysosomal binding of both wild-type and several pathogenic mutant LRRK2 proteins was enhanced in the presence of other CMA substrates, which interfered with the organization of the CMA translocation complex, resulting in defective CMA. Cells responded to such LRRK2-mediated CMA compromise by increasing levels of the CMA lysosomal receptor, as seen in neuronal cultures and brains of LRRK2 transgenic mice, induced pluripotent stem cell–derived dopaminergic neurons and brains of Parkinson's disease patients with LRRK2 mutations. This newly described LRRK2 self-perpetuating inhibitory effect on CMA could underlie toxicity in Parkinson's disease by compromising the degradation of α-synuclein, another Parkinson's disease–related protein degraded by this pathway.

27 June 2015 in Brain
Verified
Journal Article
Open access
PDF file
RARoy N. Alcalay
Roy N. Alcalay
OLOren A. Levy
Oren A. Levy
CWCheryl H. Waters
Cheryl H. Waters
SFStanley Fahn
Stanley Fahn
BFBlair Ford
Blair Ford
XZXiaokui Zhang
Xiaokui Zhang
Glucocerebrosidase (GBA) mutations have been associated with Parkinson’s disease in numerous studies. However, it is unknown whether the increased risk of Parkinson’s disease in GBA carriers is due to a loss of glucocerebrosidase enzymatic activity. We measured glucocerebrosidase enzymatic activity in dried blood spots in patients with Parkinson's disease (n = 517) and controls (n = 252) with and without GBA mutations. Participants were recruited from Columbia University, New York, and fully sequenced for GBA mutations and genotyped for the LRRK2 G2019S mutation, the most common autosomal dominant mutation in the Ashkenazi Jewish population. Glucocerebrosidase enzymatic activity in dried blood spots was measured by a mass spectrometry-based assay and compared among participants categorized by GBA mutation status and Parkinson’s disease diagnosis. Parkinson’s disease patients were more likely than controls to carry the LRRK2 G2019S mutation (n = 39, 7.5% versus n = 2, 0.8%, P < 0.001) and GBA mutations or variants (seven homozygotes and compound heterozygotes and 81 heterozygotes, 17.0% versus 17 heterozygotes, 6.7%, P < 0.001). GBA homozygotes/compound heterozygotes had lower enzymatic activity than GBA heterozygotes (0.85 µmol/l/h versus 7.88 µmol/l/h, P < 0.001), and GBA heterozygotes had lower enzymatic activity than GBA and LRRK2 non-carriers (7.88 µmol/l/h versus 11.93 µmol/l/h, P < 0.001). Glucocerebrosidase activity was reduced in heterozygotes compared to non-carriers when each mutation was compared independently (N370S, P < 0.001; L444P, P < 0.001; 84GG, P = 0.003; R496H, P = 0.018) and also reduced in GBA variants associated with Parkinson’s risk but not with Gaucher disease (E326K, P = 0.009; T369M, P < 0.001). When all patients with Parkinson’s disease were considered, they had lower mean glucocerebrosidase enzymatic activity than controls (11.14 µmol/l/h versus 11.85 µmol/l/h, P = 0.011). Difference compared to controls persisted in patients with idiopathic Parkinson’s disease (after exclusion of all GBA and LRRK2 carriers; 11.53 µmol/l/h, versus 12.11 µmol/l/h, P = 0.036) and after adjustment for age and gender (P = 0.012). Interestingly, LRRK2 G2019S carriers (n = 36), most of whom had Parkinson’s disease, had higher enzymatic activity than non-carriers (13.69 µmol/l/h versus 11.93 µmol/l/h, P = 0.002). In patients with idiopathic Parkinson’s, higher glucocerebrosidase enzymatic activity was associated with longer disease duration (P = 0.002) in adjusted models, suggesting a milder disease course. We conclude that lower glucocerebrosidase enzymatic activity is strongly associated with GBA mutations, and modestly with idiopathic Parkinson’s disease. The association of lower glucocerebrosidase activity in both GBA mutation carriers and Parkinson’s patients without GBA mutations suggests that loss of glucocerebrosidase function contributes to the pathogenesis of Parkinson’s disease. High glucocerebrosidase enzymatic activity in LRRK2 G2019S carriers may reflect a distinct pathogenic mechanism. Taken together, these data suggest that glucocerebrosidase enzymatic activity could be a modifiable therapeutic target.

1 November 2014 in Cell Reports
Verified
Journal Article
Open access
CWChris M. Woodard
Chris M. Woodard
BCBrian A. Campos
Brian A. Campos
SKSheng-Han Kuo
Sheng-Han Kuo
MNMelissa J. Nirenberg
Melissa J. Nirenberg
MNMichael W. Nestor
Michael W. Nestor
SNScott A. Noggle
Scott A. Noggle
Parkinson's disease (PD) has been attributed to a combination of genetic and nongenetic factors. We studied a set of monozygotic twins harboring the heterozygous glucocerebrosidase mutation (GBA N370S) but clinically discordant for PD. We applied induced pluripotent stem cell (iPSC) technology for PD disease modeling using the twins' fibroblasts to evaluate and dissect the genetic and nongenetic contributions. Utilizing fluorescence-activated cell sorting, we obtained a homogenous population of "footprint-free" iPSC-derived midbrain dopaminergic (mDA) neurons. The mDA neurons from both twins had ∼50% GBA enzymatic activity, ∼3-fold elevated α-synuclein protein levels, and a reduced capacity to synthesize and release dopamine. Interestingly, the affected twin's neurons showed an even lower dopamine level, increased monoamine oxidase B (MAO-B) expression, and impaired intrinsic network activity. Overexpression of wild-type GBA and treatment with MAO-B inhibitors normalized α-synuclein and dopamine levels, suggesting a combination therapy for the affected twin.

1 June 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
GTGuomei Tang
Guomei Tang
PRPuri Gutierrez Rios
Puri Gutierrez Rios
SKSheng-Han Kuo
Sheng-Han Kuo
HAHasan Orhan Akman
Hasan Orhan Akman
GRGorazd Rosoklija
Gorazd Rosoklija
DSDavid Sulzer
David Sulzer

14 June 2016 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
YGYan‐Jie Guo
Yan‐Jie Guo
SDSu‐Yan Dong
Su‐Yan Dong
XCXin‐Xin Cui
Xin‐Xin Cui
YFYa Feng
Ya Feng
TLTe Liu
Te Liu
YWYun-Cheng Wu
Yun-Cheng Wu